Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|August 2, 2016
- Pharmaceutical Technology-08-02-2016
- Volume 40
- Issue 8
Syringe Pump for Continuous Flow Chemical Processing
The Titan Syringe Pump from Syrris is a continuous flow chemical processing module suitable for lab-, pilot-, and production-scale applications.
The Titan Syringe Pump from Syrris is a continuous flow chemical processing module suitable for lab-, pilot-, and production-scale applications. The pump is chemically-resistant and combines drive motors, valve design, and software control to deliver flow rates from 1 to 250 mL/min.
The pump, designed for reliable scale-up, operates at pressures up to 20 bar and viscosities up to 1000 cP, delivering precisely controlled flow rates for extended periods. The pump contains removable cassettes that allow straightforward serving of syringes and enable seals to be rapidly changed with minimal tools required. A built-in backwash feature prolongs seal lifetime and maintains the cleanliness of pistons and cylinders, which also helps to prevent degradation of air-sensitive chemicals and protect users. The Titan Syringe Pump can be controlled manually via the Titan Remote Display touch screen or fully automated through PC software, and it is compatible with a wide range of chemical reaction systems.
Articles in this issue
about 10 years ago
Designing Flexible Aseptic Containment Systemsabout 10 years ago
Using 3D Printing for Solid-Dosage Drugsabout 10 years ago
One Strategy for Updating an Aging Facilityabout 10 years ago
Downstream Processing Continues to Worry CMOsabout 10 years ago
Quality Manufacturing Key to Stemming Drug Shortagesabout 10 years ago
New Equipment Meets Need for Innovation in Pharma Manufacturingabout 10 years ago
Evaluating Technology and Innovation in Biopharmaceutical Manufacturingabout 10 years ago
FDA and the Emerging Technology of 3D Printingabout 10 years ago
Measuring Equipment and Manufacturing Trendsabout 10 years ago
Manufacturing and Distribution Boundaries BlurRelated to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.